Systemic and local estrogen metabolism in healthy women compared to endometrial cancer patients
- Conditions
- endometrial cancerestrogen metabolismestrone17beta-estradiol17beta-hydroxysteroid dehydrogenasesteroid sulfatasesteroid sulfotransferasearomataseserum hormone levelsendometrial tissue
- Registration Number
- NL-OMON25168
- Lead Sponsor
- Maxima Medisch Centrum, Veldhoven
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Patients with;
- Hysterectomy needs to be preformed because of endometrial cancer or benign indication (like prolapse, menorrhagia, uterus myomatosis)
Exclusion Criteria
Patients with;
- Neoadjuvant treatment defined as chemotherapy and/or radiotherapy
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be the difference between premenopausal, postmenopausal and endometrial cancer patients in the local tissue enzyme mRNA levels analysed by rt-PCR and described as fold change compared to housekeeping genes. Enzyme activity levels analysed by LCMS for HSD17B1, HSD17B2, STS, SULT1E1, ARO will be described in pmol/mg/hour. Systemic serum steroid levels (see for specification section 5.3 study procedures).will be measured and described in ng/ml or pg/ml.
- Secondary Outcome Measures
Name Time Method Secondary objectives are; differences in BMI, presence of diabetes, presence of hypertension, hormone use, parity, and history of other malignancies.